Clinical trial NCT04018209: Aquagenic Pruritus in Myeloproliferative Neoplasms
Official title: Aquagenic Pruritus in Myeloproliferative Neoplasms
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms
Keywords: Pruritus
Myeloproliferative Neoplasms
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2019-07-12
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with one of three Philadelphia positive non-chromosome myeloproliferative neoplasms: polycythemia vera (PV), essential thrombocythemia (TE) or primary myelofibrosis (PMF).

And suffering (or having suffered) from aquagenic pruritus.

Brief summary: Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms.

Prospective work based on the distribution of a dedicated questionnaire.

Detailed description: Patients with myeloproliferative neoplasms identified and followed in French Hospitals. Patients could be followed for polycythemia vera or essential thrombocythemia or primary myelofibrosis.

Distribution of the questionnaire to each patient with myeloproliferative neoplasm (treated or not) suffering from aquagenic pruritus.

Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at the end.

Eligibility criteria: Inclusion Criteria:

* Patients with one of three non-chromosomal Philadelphia-positive myeloproliferative neoplasms: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
* Suffering (or having suffered) from aquagenic pruritus.
* No age limit, but major
* Patient having formulated his non-opposition

Exclusion Criteria:

* Patients with MPN with non-aquagenic pruritus,
* Patients with another hematologic disease and aquagenic pruritus
* Patients unable to complete the questionnaire.
* Patients with physical or mental disabilities to formulate non-opposition
* Refusal of participation

Primary outcomes:
measure: Description of pruritus in patients with myeloproliferative neoplasms
timeFrame: at the time of questionnaire completion (Day 0)
Secondary outcomes:
measure: Description of therapies used to treat pruritus
timeFrame: at the time of questionnaire completion (Day 0)
Other outcomes:
Locations:
city: Lyon
country: France
facility: 05
state: Auvergne Rhônes-alpes
city: Quimper
country: France
facility: 10
state: Brestagne
city: Morlaix
country: France
facility: 11
state: Bretagne
city: Saint-Brieuc
country: France
facility: 09
state: Bretagne
city: Saint-Louis
country: France
facility: 07
state: Grand Est
city: Annecy
country: France
facility: 03
state: Haute-Savoie
city: Roubaix
country: France
facility: 04
state: Hauts-de-France
city: Rochefort
country: France
facility: 08
state: Nouvelle Aquitaine
city: Angers
country: France
facility: 06
state: Pays de la Loire
city: Villejuif
country: France
facility: 02
state: Val-de-marne
city: Brest
country: France
facility: 01
Study officials:
References: